Efficacy, compliance and economics of amlodipine besylate and benazepril hydrochloride tablets Ⅱ in treatment of essential hypertension

Wu Xiaoying; Yin Yanbin; Chen Yan; Dai Wenxin

doi:10.3760/j.issn.1673-4777.2020.04.010

Abstract：Objective To evaluate the efficacy, compliance and economics of amlodipine besylate and benazepril hydrochloride tablets (Ⅱ) in treatment of primary mild to moderate hypertension. Methods A total of 100 patients with primary mild to moderate hypertension admitted to Hainan General Hospital from January 2016 to December 2018 were randomly assigned to have single pill combination ( SPC ) using amlodipine besylate and benazepril hydrochloride tablets (Ⅱ) and amlodipine tablets plus benazepril tablets for 12 weeks. Blood pressure control, patient compliance, adverse reactions, overall efficacy and drug expense were analyzed. Results The total effective rate was similar between SPC and two drugs combination [ 96. 0％( 48/50 ) vs 94. 0％( 47/50 ) ] (P=0. 646). Sitting systolic pressure and diastolic pressure significantly decreased after both treatments[systolic pressure:(133 ±14)mmHg vs (150 ±13)mmHg, (128 ±11)mmHg vs (150 ±12)mmHg; diastolic pressure:(87±8)mmHg vs (100 ±5)mmHg, (83 ±6)mmHg vs (99 ±3)mmHg](all P <0.05), but no statistical difference was observed between the two group(P>0. 05). There was no significant difference in adverse reaction rate between the two treatments(P=0. 749). The compliance rate with SPC was significantly higher than that with two drugs combination [ 94. 0％ ( 47/50 ) vs 82. 0％ ( 41/50 ) ] ( P = 0. 037 ) . The total expense of SPC was 15298. 50 yuan, which was reduced by 43. 2％ compared with the expense of drug combination(26933. 08 yuan). Conclusions Amlodipine besylate and benazepril hydrochloride tablets (Ⅱ) show equal efficacy compared with the combination of amlodipine tablets plus benazepril tablets, and no obvious adverse reactions are observed. SPC shows advantages in optimizing blood pressure management, improving compliance and reducing medical cost.